New biomanufacturing platform could enable healthcare workers to make vaccines when and where they need them.
Credit: Justin Muir
Membranes unlock potential to vastly increase cell-free vaccine production
By cracking open a cellular membrane, Northwestern University synthetic biologists have discovered a new way to increase production yields of protein-based vaccines by five-fold, significantly broadening access to potentially lifesaving medicines.
In February, the researchers introduced a new biomanufacturing platform that can quickly make shelf-stable vaccines at the point of care, ensuring they will not go to waste due to errors in transportation or storage. In its new study, the team discovered that enriching cell-free extracts with cellular membranes — the components needed to made conjugate vaccines — vastly increased yields of its freeze-dried platform.
The work sets the stage to rapidly make medicines that address rising antibiotic-resistant bacteria as well as new viruses at 40,000 doses per liter per day, costing about $1 per dose. At that rate, the team could use a 1,000-liter reactor (about the size of a large garden waste bag) to generate 40 million doses per day, reaching 1 billion doses in less than a month.
“Certainly, in the time of COVID-19, we have all realized how important it is to be able to make medicines when and where we need them,” said Northwestern’s Michael Jewett, who led the study. “This work will transform how vaccines are made, including for bio-readiness and pandemic response.”
The research was published today (April 22) in the journal Nature Communications.
Jewett is a professor of chemical and biological engineering at Northwestern’s McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. Jasmine Hershewe and Katherine Warfel, both graduate students in Jewett’s laboratory, are co-first authors of the paper.
The new manufacturing platform — called in vitro conjugate vaccine expression (iVAX) — is made possible by cell-free synthetic biology, a process in which researchers remove a cell’s outer wall (or membrane) and repurpose its internal machinery. The researchers then put this repurposed machinery into a test tube and freeze-dry it. Adding water sets off a chemical reaction that activates the cell-free system, turning it into a catalyst for making usable medicine when and where it’s needed. Remaining shelf-stable for six months or longer, the platform eliminates the need for complicated supply chains and extreme refrigeration, making it a powerful tool for remote or low-resource settings.
In a previous study, Jewett’s team used the iVAX platform to produce conjugate vaccines to protect against bacterial infections. At the time, they repurposed molecular machinery from Escherichia coli to make one dose of vaccine in an hour, costing about $5 per dose.
“It was still too expensive, and the yields were not high enough,” Jewett said. “We set a goal to reach $1 per dose and reached that goal here. By increasing yields and lowering costs, we thought we might be able to facilitate greater access to lifesaving medicines.”
Jewett and his team discovered that the key to reaching that goal lay within the cell’s membrane, which is typically discarded in cell-free synthetic biology. When broken apart, membranes naturally reassemble into vesicles, spherical structures that carry important molecular information. The researchers characterized these vesicles and found that increasing vesicle concentration could be useful in making components for protein therapeutics such as conjugate vaccines, which work by attaching a sugar unit — that is unique to a pathogen — to a carrier protein. By learning to recognize that protein as a foreign substance, the body knows how to mount an immune response to attack it when encountered again.
1 billion: Number of doses new platform could generate in less than a month
Attaching this sugar to the carrier protein, however, is a difficult, complex process. The researchers found that the cell’s membrane contained machinery that enabled the sugar to more easily attach to the proteins. By enriching vaccine extracts with this membrane-bound machinery, the researchers significantly increased yields of usable vaccine doses.
“For a variety of organisms, close to 30% of the genome is used to encode membrane proteins,” said study co-author Neha Kamat, who is an assistant professor of biomedical engineering at McCormick and an expert on cell membranes. “Membrane proteins are a really important part of life. By learning how to use membrane proteins effectively, we can really advance cell-free systems.”
Original Article: Membranes unlock potential to vastly increase cell-free vaccine production
More from: Northwestern University | Robert R. McCormick School of Engineering and Applied Science
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cell-free vaccine production
- First cancer vaccine trial finds jabs ‘weaponise immune system to attack killer tumours in 48 hours’
A NEW mRNA cancer vaccine can reprogram the immune system to attack tumours within 48 hours, a study shows. The first-ever human clinical trial of four adult patients showed the jab helps fight ...
- Stem Cells News
How Gene Activity Modulates the Amount of Immune Cell Production in Mice Jan. 26 ... Painless, and Feeder-Free Dec. 21, 2023 — Scientists have developed an efficient, non-invasive, and pain ...
- Applied DNA gets contract from HDT Bio for vaccine development under a ‘Project NextGen: Enabler’
Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ...
- Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
Under the terms of the contract, Applied DNA will supply Linea™ DNA IVT templates to HDT Bio for use in conjunction with its LION™ formulated repRNA (self-replicating RNA) vaccination platform. The ...
- Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
The Project seeks to facilitate the rapid production of vaccines during outbreaks/pandemics ... The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA's ...
Go deeper with Google Headlines on:
Cell-free vaccine production
[google_news title=”” keyword=”cell-free vaccine production” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Biomanufacturing platform
- Biointelligence raises $5 million for biomanufacturing efficiency platform
Sherbrooke, Qué.-based Biointelligence Technologies has raised $5 million CAD in seed funding for its platform aimed at making industrial fermentation bioprocesses less wasteful. Lead investor ...
- Is Stardew Valley cross-platform?
This was many years ago, and there has been no further information about cross-platform play since, so it seems very unlikely that we will see support for this functionality come to Stardew Valley.
- The best cross-platform games for PS5, PS4, Xbox Series X, Xbox One, PC and Switch
What are the best cross-platform games to play? It depends entirely on what you mean by “cross-platform games.” The term refers to two distinct, but related, concepts, and both involve playing ...
- Best online learning platform of 2024
We also assessed the pricing plans and what kind of users each learning platform would be best suited for, among other things. Below we list what we think are the best online learning platforms ...
- Germany's Merck breaks ground on $321m biomanufacturing center
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
Go deeper with Google Headlines on:
Biomanufacturing platform
[google_news title=”” keyword=”biomanufacturing platform” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]